Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small RNA: can RNA interference be exploited for therapy?

Nathan R Wall1, Yang Shi

  • 1Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.

Lancet (London, England)
|October 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular Vesicles in Diffuse Midline Glioma: Emerging Mediators of Radiation Response and Therapeutic Resistance.

Cancers·2026
Same author

Seco-Duocarmycin SA Augments the Impact of Proton Radiation on Human Glioblastoma Cells.

International journal of molecular sciences·2026
Same author

Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines.

International journal of molecular sciences·2025
Same author

Integrating gold nanostars into condensed DNA.

Biochimica et biophysica acta. General subjects·2025
Same author

A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs.

Cancers·2024
Same author

Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential.

Biochimica et biophysica acta. Reviews on cancer·2024
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

RNA interference (RNAi) offers a powerful method for gene silencing, with small interfering RNAs (siRNAs) showing promise for genetic therapies. Further development in delivery and stability is needed for clinical applications.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • RNA interference (RNAi) is a natural process of gene silencing.
  • Small interfering RNAs (siRNAs) are key effectors of RNAi, enabling sequence-specific gene knockdown.
  • RNAi is being explored for therapeutic applications in viral infections, cancers, and genetic disorders.

Purpose of the Study:

  • To explore the potential of RNA interference (RNAi) for gene function studies and therapeutic applications.
  • To investigate the use of small interfering RNAs (siRNAs) for targeted gene silencing.
  • To identify novel therapeutic targets by studying gene families involved in cancer-relevant pathways.

Main Methods:

  • Utilizing synthetic small interfering RNAs (siRNAs) for sequence-specific gene inhibition.

Related Experiment Videos

  • Employing plasmid and viral vectors for efficient siRNA and short-hairpin RNA (shRNA) expression.
  • Developing RNA interference vectors to suppress specific gene families, such as de-ubiquitinating enzymes.

    • Main Results:

    • Demonstrated that siRNAs can selectively inhibit endogenous gene expression.
    • Identified the cylindromatosis tumour suppressor gene (CYLD) as a regulator of NF-kappaB activation and apoptosis resistance.
    • Showcased stable gene expression inhibition using plasmid and viral vector-based shRNA expression systems in vitro and in vivo.

    Conclusions:

    • RNAi, particularly using siRNAs and shRNAs, provides a robust tool for gene function analysis and potential therapeutic interventions.
    • Efficient and stable delivery of siRNA/shRNA to target tissues remains a critical area for clinical translation.
    • Further research and refinement of delivery systems are paving the way for clinical trials utilizing RNAi-based therapies.